European Pharmaceutical Pricing and Reimbursement conference
Upcoming SlideShare
Loading in...5
×
 

European Pharmaceutical Pricing and Reimbursement conference

on

  • 2,023 views

 

Statistics

Views

Total Views
2,023
Views on SlideShare
2,023
Embed Views
0

Actions

Likes
0
Downloads
23
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

European Pharmaceutical Pricing and Reimbursement conference European Pharmaceutical Pricing and Reimbursement conference Document Transcript

  • REGISTER BY 30TH JUNE AND RECEIVE A £300 DISCOUNT SMi present their 17th Annual Conference on... European Pharmaceutical Pricing and Reimbursement Monday 31st October & Tuesday 1st November 2011 Radisson Blu Hotel Basel, Switzerland KEYNOTE SPEAKERS: OTHER SPEAKERS INCLUDE: Andrea Rappagliosi Markus Jahn Vice President, European Government Manager Pricing Affairs & Head of Brussels Office Novartis Pharma GlaxoSmithKline Henderson Azevedo Market Pricing Director Northern & Peter Kolominsky-Rabas Central Europe and Canada Director, Interdisciplinary Centre Novartis Pharma Health Technology Assessment and Jan Posthumus Public Health Head of Market Access & Market Research Basilea Pharmaceutica International Ltd. Martina Garau Senior Economist Frank Thoss, Lawyer Office of Health Economics Strategic Policy Affairs VFA Isabel Henkel Elke Hunsche Director Access & Reimbursement Director, Head of Health Economics & Johnson & Johnson Medical Pricing 2011 has brought huge changes to the Actelion Pharmaceuticals healthcare landscape – the global economic crisis and rising healthcare costs have caused governments to take cautious approaches CONFERENCE HIGHLIGHTS towards pricing and reimbursement. With an • Get to grips with the facts and consequences of Germanys AMNOG essential review of the key challenges and • Debate EU policy challenges in access to medicines in Europe developments in VBP, AMNOG and other EU • Analyse market access in new emerging markets policy challenges, SMis 17th annual European • Understand Value Based Pricing: Principles and practice in the UK Pharmaceutical Pricing and Reimbursement policy context • Get up to speed with the latest regulations within P&R Conference will feature presentations on the • Discover the value of collaboration in HTA and managed entry latest P&R issues from the industry’s most schemes senior professionals and academics. PLUS TWO INTERACTIVE POST-CONFERENCE WORKSHOPS Sponsored by Wednesday 2nd November 2011, Radisson Blu Hotel Basel, Basel, Switzerland Workshop A - Market Access in Emerging Markets: Overview of growth opportunities and key market access challenges in emerging markets Hosted by Gustav Ando, Director, Healthcare & Pharma, IHS Global Insight, Aparna Krishnan, Manager, Emerging Markets, Healthcare & Pharma, IHS Global Insight, Ruben Gennero, Research Analyst, Healthcare & Pharma, IHS Global Insight 8.30am - 12.30pm Workshop B - Cooperation with Payors as a Means for AttainingReimbursement Hosted by Norbert Jersch, Partner, Roman Rittweger Advisors in Healthcare 1.00pm - 5.00pmwww.smi-online.co.uk/2011europricing.aspRegister online and receive full information on all of SMi’s conferencesAlternatively fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
  • European Pharmaceutical Pricing and ReimbursementDay One | Monday 31st October 2011 www.smi-online.co.uk8.30 Registration & coffee ORPHAN DRUGS9.00 Chairmans opening remarks Donald Macarthur, Global Pharmaceutical Business Analyst 1.50 Orphan Drug P&R in Europe: Are the payers biting back? • Situation with approved orphan drugs in EU-5 EU POLICY CHALLENGES • Vital role of funding KEYNOTE ADDRESS • What payers wont buy9.10 EU policy challenges in access to medicines in Europe: the value of collaboration in HTA and managed entry schemes • How and where HTA limits access • Assessment and Appraisal: is there a scope for European • Successful company strategies collaboration in HTA to prove clinical value to governments and payers? Donald Macarthur, Global Pharmaceutical Business Analyst • How the new challenges of “valuable innovation” can be addressed in order to meet priorities in healthcare? 2.30 Orphan Drug Challenges in Europe and Future Opportunities for • Will Managed Entry Schemes provide a refined tool to address uncertainties in patients access? Development • Can stakeholders contribute effectively to the setting of shared • Critical success factors and challenges rules? Andrea Rappagliosi, Vice President, European Government Affairs & • Future opportunities in orphan drug development Head of Brussels Office, GlaxoSmithKline Elke Hunsche, Director, Head of Health Economics & Pricing, KEYNOTE ADDRESS Actelion Pharmaceuticals9.50 The role of HTA agencies • HTA expectations in late phase development • HTA agency policy and practice globally: comparing and contrasting 3.10 Afternoon Tea different models • Opportunities for Early Engagement with HTA agencies Peter Kolominsky-Rabas, Director, Interdisciplinary Centre, Health 3.40 Market Access to Orphan Drugs in Italy Technology Assessment and Public Health • Mechanisms for “early reimbursement” of orphan drugs10.30 Morning Coffee • The pricing and reimbursement process for orphan drugs • Orphan drugs and innovation AMNOG Laura Crippa, Director, Market Access and Pricing, Temas S.r.l.11.00 Pricing in Germany with new AMNOG Unipersonale • Benefit assessment of launch drugs and in-market brands • Pricing roadmap after benefit assessment - fixed price or central price-negotiation 4.20 Change Drivers in pricing and reimbursement practice • First experiences with the new regulation and outlook • Changing macroeconomic environment – countries under economic Markus Jahn, Manager Pricing, Novartis Pharma pressure11.40 Germanys AMNOG: Facts and consequences • Envolving stakeholder roles – the patient • Regulation of the German pharmaceutical market before AMNOG before Jan 1st 2011 • P&R evaluation price setting and reimbursement mechanisms • AMNOG-process of early benefit assessment and central price- • Increased use of generics and similar - perceptions negotiations in detail • Possible consequences for other countries Jorge Wernli, Vice President, Global Pricing and Government Affairs, Frank Thoss, Lawyer, Strategic Policy Affairs, VFA - German Vifor Pharma Association of Research-Based Pharmaceutical Companies12.20 Networking Lunch 5.00 Chairman’s Closing Remarks and Close of Day One Register online at www.smi-online.co.uk/2011europricing.asp • AlternatPHARMACEUTICAL FORWARD PLANNERJune 2011 18/19 Pharmaceutical and Clinical Trial Logistics Asia 19/20 COPD: Novel Therapeutics and Management27/28 RNAi, miRNA, siRNA Pacific (Singapore) Strategies29/30 Pharmaceutical Portfolio & Product 20/21 Pre Filled Syringes Asia (Singapore) 24/25 Point of Care Diagnostics - Market Opportunities and Life Cycle Management Technology Trends29/30 Pharmaceutical Nanotechnology September 201129/30 KOL Management and MSL 19/20 Biomarkers in Clinical Trials November 2011 Best Practice in Europe (Munich, Germany) 26/27 Biosimilars and Biobetters 31 Oct/1 Nov European Pharmaceutical Pricing 28/29 KOL Liaison and MSL Best Practice & Reimbursement (Switzerland)July 2011 16/17 Clinical Trials in CNS06/07 ADMET October 2011 21/22 Cell Based Assay06/07 Social Media in the Pharmaceutical Industry 03/04 Managing Partnerships with CROs11/12 BioBanking 10/11 Pharmaceutical m-Health December 2011 12/13 GP Commissioning 5/6 Cold Chain DistributionAll conferences take place in central London, UK – unless indicated otherwise in brackets Supported by
  • European Pharmaceutical Pricing and Reimbursementk/2011europricing.asp Day Two | Tuesday 1st November 2011 8.30 Re- Registration & coffee 12.20 Networking Lunch 9.00 Chairmans opening remarks Neil Palmer, President and Principal Consultant, PDCI Market 1.50 The patient’s role in market access in public healthcare systems Access Inc • Increasing patient choices in an equitable way ESTABLISHED MARKET OVERVIEW • Patient-reported outcome measures KEYNOTE ADDRESS • Achieving maximum levels of patient and market access 9.10 Value based pricing - Principles and practice in the UK policy context Bertram Haussler, Chairman of the Board of Management, IGES • Approaches to value base pricing (VBP) Insitut. Berlin • Lessons learnt from international experience of VBP • Introducing VBP in the UK: - The Department of Health consultation - How might VBP be implemented and what are the expected 2.30 The access marketing mix for launch products consequences? • Access marketing for the different stakeholders Martina Garau, Senior Economist, Office of Health Economics • Preparation for launch from an access perspective: timelines, KEYNOTE ADDRESS tools and techniques 9.50 Market access in European Established Markets • Overview of key stakeholders in Europe’s established markets Jan Posthumus, Head of Market Access & Market Research, Basilea • Who are the key agencies in the market • Understanding HTA regulations in Europe Pharmaceutica International Ltd Isabel Henkel, MPH, Director Access & Reimbursement, Johnson & Johnson Medical 3.10 Afternoon Tea 10.30 Morning Coffee MARKET ACCESS 3.40 Latest regulations within pricing and reimbursement 11.00 Market access in emerging markets • EU initiatives in pricing and reimbursement • Recent developments and future trends • Opportunities and threats - a pharmaceutical industry perspective • Risk Sharing Agreements • Lessons from developed markets • Patient Access Schemes Henderson Azevedo, Market Pricing Director Northern & Central Europe and Canada, Novartis Pharma James Killick, Partner, White & Case LLP 11.40 Canadian Market Access Update • Overview of Canadian health care system and pharmaceutical 4.20 Sweden Market Access update funding • Price regulation and the new Patented Medicine Prices Review • Cost-effectiveness and cost utility Board (PMPRB) guidelines • What is the value at stake? • CADTH - Common Drug Review (CDR), pCODR (oncology drugs), INESSS (Quebec), provincial and private reimbursement schemes • Price analysis for new product candidates • Implications of the Ontario 25% pricing rule for generics and the evolution of Product Listing Agreements (PLAs) Jacob Brun, Pricing & Reimbursement Director, AstraZeneca • Outlook for Canadian pricing & reimbursement W. Neil Palmer, President & Principal Consultant, PDCI Market Access Inc. 5.00 Chairman’s Closing Remarks and Close of Conferencetively fax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711 Sponsored by SPONSORSHIP AND EXHIBITION OPPORTUNITIES PDCI Market Access (PDCI) is Canada’s leading SMi offer sponsorship, exhibition, advertising and branding packages, pharmaceutical pricing and reimbursement uniquely tailored to complement your company’s marketing strategy. consultancy. Established in 1996, the firm assists Prime networking opportunities exist to entertain, enhance and expand clients navigate the complex pricing and market your client base within the context of an independent discussion specific access challenges facing pharmaceutical manufacturers. In particular, PDCI helps pharmaceutical to your industry. Should you wish to join the increasing number of companies develop successful pricing and reimbursement strategies and prepare comprehensive companies benefiting from sponsoring our conferences please call: submissions to CADTH/CDR, INESSS, public & private payers and the Patented Medicine Prices Alia Malick on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk Review Board (PMPRB). The Canadian market access capabilities are supported by PDCI’s Want to know how you can get involved? comprehensive public payer claims database and the industry standard Canadian Drug Benefits Plan Interested in promoting your pharmaceutical services to this market? (CDBP) reference guide. PDCI also maintains extensive databases of international pharmaceutical prices in support of PDCI’s international payer research and global pricing strategy engagements. Contact Kiran Sharma, SMi Marketing on +44 (0)20 7827 6050, or Headquartered in Ottawa, PDCI features a senior team of bilingual market access professionals with email: ksharma@smi-online.co.uk extensive pricing and reimbursement experience. www.pdci.ca
  • HALF-DAY POST-CONFERENCE WORKSHOP Wednesday 2nd November 2011Radisson Blu Hotel Basel, Basel, Switzerland. 8.30am - 12.30pm Workshop AMarket Access in Emerging Markets Overview of growth opportunitiesand key market access challenges in emerging markets.In association withOverview of WorkshopIHS Global Insight Country Intelligence provides constantlyupdated analysis of the business conditions, economicprospects and risks in over 200 countries.Find out about the growth opportunities in emerging marketsincluding BRIC-MT countries, Philippines, Indonesia, Kenyaand South Africa. Understand the evolution of healthcarepolicies and their impact on pricing and reimbursement.Identify the unique challenges to market access in thesecountries in the context of global pricing and reimbursementtrends.• Monitor and understand developments as economic and political conditions change• Assess growth and development potential for individual economies and regional markets• Analyze relative risks among countries around the worldAgenda8.30 Registration and coffee9.00 Welcome and Introduction9.10 Emerging Versus Advanced Markets • Forecasted Outlook in Emerging Versus Advanced Markets • Growth Opportunities in Emerging Versus Advanced Markets • The Unique Challenges of Emerging Markets9.50 BRIC-MT Markets Overview • Best Growth Opportunities in the BRIC-MT Region10.30 Coffee Break11.00 Latin America Overview • P&R Regulations Evolution in Latin America11.40 The Next Frontier: Second Tier Emerging Markets • Growth opportunities and challenges in Philippines, Indonesia, Kenya, South Africa12.30 Close of workshopAbout the Workshop Leaders: Ruben Gennero is the healthcare analyst for Latin American markets and Spain. Before joining IHS Global Insight, Ruben worked at the Chilean Ministry of Health as a Health Management and was Policy Advisor for the Chilean healthauthorities, participating in healthcare and pharmaceuticalreforms assessments and carrying out different proposals asproject manager. He left the Ministry of Health and worked asan external advisor of GlaxoSmithkline Chile, focusing onhealth policy and market access issues. Aparna Krishnan is Manager/Senior Research Analyst at IHS Global Insight’s Healthcare & Pharma Practice in London in charge of the practice’s subscription services namely World Markets Healthcare and Pricing &Reimbursement. Her areas of expertise includes corporatestrategies, health economics, market access, drug pricingand reimbursement and generics in the pharmaceutical andhealthcare space. Gustav Ando leads the Healthcare and Pharma Practice at IHS. Formerly a healthcare analyst, he has extensive experience in the fields of market access, therapeutic development, drug safety, emerging markets and health outcomes. He hasdeveloped numerous information tools for pharmaceuticalcompanies and has led consulting projects on global pricingtrends, reference pricing, risk-sharing agreements,therapeutic-specific market access strategies, bespokedatabase creation and internal corporate P&R strategybenchmarking.
  • HALF-DAY POST-CONFERENCE WORKSHOP Wednesday 2nd November 2011Radisson Blu Hotel Basel, Basel, Switzerland. 1.00pm - 5.00pm Workshop BCooperation with Payors as a Means for Attaining Reimbursement In association with Roman Rittweger Advisors in HealthcareOverview of WorkshopThe pricing and reimbursement landscape is increasinglydirected by cost-benefit analyses through governmentagencies closely linked to payors and governments costcontainment initiatives. In order to convince payors of apharmaceutical products benefit, seeking cooperationbetween the pharmaceutical industry and payors is ofutmost importance. In this interactive workshop, we willwork out strategies for approaching the relevant playersof public health systems in order to provide them witharguments for supporting a products reimbursement.“Traditional”cost-saving value added services such asdisease management, targeted patient training or cost-sharing schemes will be addressed as well as promisingnew opportunities from linking smartphone apps topatient management platforms and to generateoutcomes data from that, e.g. register studies.This Workshop Will Cover:• How payors can be motivated to enter pharma cooperations• Some current best practice examples and new ideas• Development and discussion of participants own ideas for value added servicesAgenda1.00 Registration & Coffee1.30 Welcome and introduction1.40 Reimbursement decision-making in key European countries • The pivotal position of public payors • Challenges for the pharmaceutical industry • Potential new opportunities2.10 Interactive work in two-person small teams, supported by the workshop leader • Concrete services adding value to products to be chosen by workshop participants • Possible strategies for approaching public payors3.50 Coffee Break3.50 Presentation and discussion of ideas developed in the working teams5.00 End of WorkshopFor more information and updates visit the conferencewebsite at www.smi-online.co.uk/2011europricing.aspAbout the Workshop Leader: Norbert Jersch PhD is partner of Roman Rittweger Advisors in Healthcare. For several years, THEgained business experience at ABOUT he SMi PHARMACEUTICAL TEAM Roche have been where he hadin the SMi Diagnostics involved developed the diabetes home monitoring 1993 and He pharmaceutical industry since market. became VP of global product planning and have developed a series of informative andmarketing for the diabetes care product line. Norbert niche events, covering the latest issues andJersch joint and managed two small IT companies whichdeveloped software for documentation and Events developments surrounding the industry. QM and bring together senior industry professionals andprovided IT services to physicians. In 2002 he managed serving companies who have a focus on being at the4sigma GmbH, an innovative service provider for payorsandforefront of developments in this management. After a market leader in disease area. SMi aim tohaving restructured and topical discussion its daughters generate informed the company and through theNorbert Jersch entered into theand executive briefings. medium of both conferences consulting business. Withhis expertise from implementing diabetes care and not Our pharmaceutical events are research-based andonly diabetes products he became a pioneer in diabetes content driven with regular contact with majordisease management. He successfully set up excellent industry personnel and cover a wide range of industryrelations with medical and governmental organizations sectors. For more information, please visit www.smi-including IDF and WHO. He was the organizer of the firstWorld Diabetes Day in 1991. For the last few years he has online.co.uk/pharmabeen working on value added service programs and oneHealth and IT solutions for Pharma and Medtechcompanies.
  • EUROPEAN PHARMACEUTICAL PRICING AND REIMBURSEMENT Conference: Monday 31st October & Tuesday 1st November 2011, Radisson Blu Hotel Basel, Switzerland Workshop: Wednesday 2nd November 2011, Switzerland 4 WAYS TO REGISTER www.smi-online.co.uk/2011europricing.aspFAX your booking form to +44 (0) 870 9090 712 POST your booking form to: Events Team, SMi Group Ltd, Great GuildfordPHONE on +44 (0) 870 9090 711 Business Square, 30 Great Guildford Street London, SE1 0HS, UK EARLY BIRD □ Book by 30th June to receive £300 off the conference price DISCOUNT CONFERENCE PRICES I would like to attend: (Please tick as appropriate) Fee □ Conference & Interactive Workshops (A & B) £2597.00 □ Conference & One Interactive Workshop £1998.00 Please indicate which workshop you wish to attend: Workshop A □ Workshop B □Unique Reference Number □ Conference only £1399.00 □ Two Half-Day Workshops (A & B) £1198.00Our Reference LVP-008 □ One Interactive Workshop £599.00 Please indicate which workshop you wish to attend: Workshop A □ Workshop B □DELEGATE DETAILS PROMOTIONAL LITERATURE DISTRIBUTIONPlease complete fully and clearly in capital letters. Please photocopy for additional delegates. □ Distribution of your company’s promotional literature to all conference attendees £999.00 + VAT £1198.80Title: Forename: GROUP DISCOUNTS AVAILABLESurname: The conference fee includes refreshments, lunch, conference papers and accessJob Title: to the Document Portal containing all of the presentations.Department/Division:Company/Organisation: VENUE Radisson Blu Hotel Basel, SwitzerlandEmail: □ Please contact me to book my hotelAddress: Alternatively call us on +44 (0) 870 9090 711, email: hotels@smi-online.co.uk or fax +44 (0) 870 9090 712Town/City:Post/Zip Code: Country: DOCUMENTATIONDirect Tel: Direct Fax: I cannot attend but would like to purchase access to the following Document Portal/paper copy documentation Price TotalMobile: □ Access to the conference documentationSwitchboard: on the Document Portal £499.00 + VAT £598.80 □ The Conference Presentations – paper copy £499.00 - £499.00Signature: Date: (or only £300 if ordered with the Document Portal)I agree to be bound by SMis Terms and Conditions of Booking.ACCOUNTS DEPT PAYMENTTitle: Forename: Payment must be made to SMi Group Ltd, and received before the event, by one of theSurname: following methods quoting reference P-008 and the delegate’s name. Bookings made within 7 days of the event require payment on booking, methods of payment are below. PleaseEmail: indicate method of payment:Address (if different from above): □ UK BACS Sort Code 300009, Account 00936418 □ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU Swift (BIC): LOYDGB21013, Account 00936418 IBAN GB48 LOYD 3000 0900 9364 18Town/City: □ Cheque We can only accept Sterling cheques drawn on a UK bank.Post/Zip Code: Country: □ Credit Card □ Visa □ MasterCard □ American Express All credit card payments will be subject to standard credit card charges.Direct Tel: Direct Fax: Card No: □□□□ □□□□ □□□□ □□□□Terms and Conditions of Booking Valid From □□/□□ Expiry Date □□/□□ CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX cardPayment: If payment is not made at the time of booking, then an invoice will be issued and must bepaid immediately and prior to the start of the event. If payment has not been received then credit carddetails will be requested and payment taken before entry to the event. Bookings within 7 days ofevent require payment on booking. Access to the Document Portal will not be given until paymenthas been received. Cardholder’s Name:Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, anotherdelegate to take your place at any time prior to the start of the event. Two or more delegates maynot ‘share’ a place at an event. Please make separate bookings for each delegate. Signature: Date:Cancellation: If you wish to cancel your attendance at an event and you are unable to send a I agree to be bound by SMis Terms and Conditions of Booking.substitute, then we will refund/credit 50% of the due fee less a £50 administration charge,providing that cancellation is made in writing and received at least 28 days prior to the start of the Card Billing Address (If different from above):event. Regretfully cancellation after this time cannot be accepted. We will however provide theconferences documentation via the Document Portal to any delegate who has paid but is unable toattend for any reason. Due to the interactive nature of the Briefings we are not normally able toprovide documentation in these circumstances. We cannot accept cancellations of orders placedfor Documentation or the Document Portal as these are reproduced specifically to order. If we haveto cancel the event for any reason, then we will make a full refund immediately, but disclaim anyfurther liability.Alterations: It may become necessary for us to make alterations to the content, speakers, timing,venue or date of the event compared to the advertised programme.Data Protection: The SMi Group gathers personal data in accordance with the UK Data ProtectionAct 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other VATproducts and services. Unless you tick here □ we may also share your data with third parties VAT at 20% is charged on Document Portal and Literature Distribution for all UK customers and foroffering complementary products or services. If you have any queries or want to update any of thedata that we hold then please contact our Database Manager databasemanager@smi-online.co.uk those EU customers not supplying a registration number for their own country here:or visit our website www.smi-online.co.uk/updates quoting the URN as detailed above youraddress on the attached letter. ____________________________________________________________________________ If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email them at events@smi-online.co.uk